Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-Week results of POWER 3

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 1, 2007, Pages 24-31

  Molina, Jean Michel ^a,i   Cohen, Calvin ^b   Katlama, Christine ^c   Grinsztejn, Beatriz ^d   Timerman, Artur ^e   Pedro, Rogério De Jesus ^f   Vangeneugden, Tony ^g   Miralles, Diego ^g   Meyer, Sandra De ^g   Parys, Wim ^h   Lefebvre, Eric ^h  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Boston Community Research Initiative of New England   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Funda??o Oswaldo Cruz   (Brazil)

^e PAM Heliopolis   (Brazil)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g TIBOTEC BVBA   (Belgium)

^h Tibotec Inc   (United States)

ⁱ SAINT LOUIS HOSPITAL   (France)

Author keywords

Darunavir; HIV RNA <50 copies mL; Protease inhibitors; TMC114

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; ENFUVIRTIDE; INDINAVIR; LOPINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; VIRUS RNA;

ACUTE RESPIRATORY FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ENCEPHALITIS; ESOPHAGUS CANDIDIASIS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; KIDNEY FAILURE; LEISHMANIASIS; LEUKOCYTE COUNT; LIVER DISEASE; LOW DRUG DOSE; LYMPHOCYTE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MUTATION; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PANCREATITIS; PANCYTOPENIA; PARTIAL THROMBOPLASTIN TIME; PNEUMONIA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SEPTIC SHOCK; SIDE EFFECT; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; RITONAVIR; RNA, VIRAL; STATISTICS AS TOPIC; SULFONAMIDES; TIME FACTORS; VIRAL LOAD;

EID: 34548212545     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181359cfb     Document Type: Article

References (23)

1. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711-718.
2. Elston RC, Yates P, Tisdale M, et al. GW433908 (908)/ritonavir (r): 48-week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype. Presented at: XVth World AIDS Conference; 2004; Bangkok.
3. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavirritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466-475.
4. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavirritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-482.
5. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
6. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC; May 4, 2006.
7. Gazzard B, on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. 2005. Available at: http://www.bhiva.org./guidelines/ 2005/HIV/guidelines2005.pdf. Accessed October 5, 2006.
8. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314-2321.
9. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.
10. Haubrich RH, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11-F18.
11. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med. 2005;13:51-57.
12. Hoetelmans R, Lefebvre E, van der Sandt I, et al. Pharmacokinetics and effect of food on TMC114, a potent next generation protease inhibitor, boosted with low-dose ritonavir. Presented at: Fifth International Workshop on Clinical Pharmacology of HIV Therapy; 2004; Rome.
13. Arasteh K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS. 2005;19:943-947.
14. AIDS Clinical Trials Group. Division of AIDS table for grading severity of adult adverse experiences. August 1992. Available at: http://rcc.tech-res- intl.com/DAIDS%20RCC%20Forms/TB_ToxicityTables_Adult_TRP_v01a.pdf. Accessed October 5, 2006.
15. Food and Drug Administration Guidance for Industry. Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval. Appendix B. Division of Antiviral Drug Products: Office of Drug Evaluation IV in the Centre for Drug Evaluation and Research (CDER); Rockville, MD; 2002.
16. Phillips A, King M. Assessing the impact of different virologic response definitions on response rates. Presented at: Ninth European AIDS Conference; 2003; Warsaw.
17. De Meyer S, Vangeneugden T, Lefebvre E, et al. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. Presented at: International HIV Drug Resistance Workshop; 2006; Sitges.
18. Gathe J Jr, De Jesus E, Falcon R, et al. Examination of factors influencing response to darunavir combined with low-dose ritonavir in POWER 1, 2, and 3: pooled 48-week analysis. Presented at: Frontiers in Drug Development for Antiretroviral Therapies; 2006; Cancun.
19. Clotet B, Bellos N, Molina J, et al. Efficacy and safety of darunavirritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-1178.
20. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
21. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
22. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr Hum Retrovirol. 2005;40:404-412.
23. Rockstroh J, Clumeck N, Spinosa Guzman S, et al. Darunavir (TMC114)/r has tolerability and efficacy benefits for treatment-experienced patients compared with control PIs: overview of the POWER trials. Presented at: Eighth International Congress on Drug Therapy in HIV infection; 2006; Glasgow.